All News
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's
MedPage Today
Genetic blood tests indicated that Bruton's tyrosine kinase (BTK) and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported, suggesting that BTK inhibitors might be useful in this population.
Read Article
Low Dose IL-2 Therapy in Sjögren’s
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.
Read Article
Potential new treatment for Sjogren's
Is there finally something new on the horizon in Sjogren’s syndrome?
Read Article
#EULAR2023 #POS0120 From Sjogren to SLE. Interim analysis of Phase 2 RCT showed primary endpoint, SRI-4 + ability to sustain pred dose to ≤5 mg/d or ≤ BL from Wk16 to 28 was achieved more in Ianalumab (Bcell depletion & BAFF-R-i) vs PBO (44% vs 9%). Advance to Phase 3 @RheumNow https://t.co/Wg29uj5yqv
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 #OP0142 From #Lupus to #Sjogren. A phase 2 RCT in China showed more patients on Telitacicept (BAFF/APRIL-i) achieved significant reduction in ESSDAI at Wk24 vs PBO. Trend to improvement in glandular function. Intriguing option & will await Phase 3 global RCT @RheumNow https://t.co/BCiohuAfP3
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significantly more patients on DAZ group met reduction in ESSDAI vs placebo. Interesting to see higher hurdle ESSDAI favoured DAZ Group. Phase 3 RCTs are underway @RheumNow https://t.co/I9uHxvRlnr
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of autoimmune disease - no evidence of overall increase in conditions. Environmental and socioeconomic factors involved in the presentation of the conditions https://t.co/3jy9NoltkG
Dr. Antoni Chan synovialjoints ( View Tweet)
Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong.
Surely this needs more investment??
CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq
David Liew drdavidliew ( View Tweet)
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's
Genetic blood tests indicated that BTK and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported.
https://t.co/DMsjFzmjPn https://t.co/X1fg9ylo7g
Links:
Dr. John Cush RheumNow ( View Tweet)
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's
Genetic blood tests indicated that BTK and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported.
https://t.co/SPmdBJ8IFh https://t.co/ad2j6XaSkK
Links:
Dr. John Cush RheumNow ( View Tweet)
Have you heard of nipocalimab? It prevents IgG-FcRn by binding to the FcRn IgG binding site. This is one to watch in our diseases (RA, Sjogren’s, SLE, myopathies.) Dr. Postolova #RWCS23 @RheumNow @RWCSmtg https://t.co/qMGA6IdtUE
Dr. Rachel Tate uptoTate ( View Tweet)
Low Dose IL-2 Therapy in Sjögren’s
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance.
https… https://t.co/r0AlTD45gG
Dr. John Cush RheumNow ( View Tweet)
Potential new treatment for Sjogren's
Is there finally something new on the horizon in Sjogren’s syndrome?
Dr. Eric Dein. ( @ericdeinmd) discusses studies presented at #ACR22.
https://t.co/YinEPKlJb2 https://t.co/YOsc159GFt
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Abstr#2033 How negative is sero-ve #Sjogren? A study discovered new autoantibodies using Peptidome Array Technology. AUC for these 8 peptides was excellent 0.97. Mainly in White/Hispanic. Need validation in other groups and association with other markers/biopsy @RheumNow https://t.co/xAFrjK9mS3
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Pike M Abstract 1113. Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study #ACRBest #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Dörner et al. Remibrutinib (BTKi) in pSS. + study in pSS! Improved ESSDAI (disease activity), no effect ESSPRI (PRO), trend to improve salivary flow, + effect on multiple labs. @RheumNow #ACR22 Abstr#1113 https://t.co/m2rvXbqq7b https://t.co/jQLyP66zX9
Richard Conway RichardPAConway ( View Tweet)
Pike M Abstract 1113. Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study #ACRBest #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Fulvio et al. Labial gland US to identify lymphoma in Sjogrens. OMERACT score of 3 in 100% of lymphoma and 35% non-lymphoma @RheumNow #ACR22 Abstr#1254 https://t.co/aspctOfGp8 https://t.co/CLhN2PTvaS
Richard Conway RichardPAConway ( View Tweet)
Plenary:
Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s
◦ Favourable safety profile
◦ Well-tolerated over 24 Wks
◦ Improved ESSDAI, salivary flow, Igs
◦ May be first effective oral disease-modifying therapy for SS
Dorner T Abs1113 https://t.co/FkgJpwKAJL #ACR22 @RheumNow https://t.co/znxMc27EBI
Dr. Antoni Chan synovialjoints ( View Tweet)
Sjogren’s is tough to study, isn’t it?
LOUiSSe (remibrutinib proof-of-concept SjS) - benefit with:
- ESSDAI (primary, obj dx activity) ✅
- auto-Ab ✅
- all patient outcomes ❎
Has already exceeded many attempts
Even then, still some limitations
ABST1113 #ACR22 @RheumNow https://t.co/NlBaFVuuPa
David Liew drdavidliew ( View Tweet)
